PMID- 33933715
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 106
DP  - 2021 Jul
TI  - MYC protein expression does not correlate with MYC abnormalities detected by FISH 
      but predicts an unfavorable prognosis in de novo acute myeloid leukemia.
PG  - 106584
LID - S0145-2126(21)00085-0 [pii]
LID - 10.1016/j.leukres.2021.106584 [doi]
AB  - While dysregulation of MYC has been implicated in acute myeloid leukemia (AML), 
      the impact of MYC protein expression in AML is less well understood. We 
      investigated the correlation of MYC protein expression by immunohistochemistry 
      (MYC-IHC) with MYC abnormalities and prognosis in adult de novo AML. MYC-IHC in 
      bone marrow of patients with untreated AML (n = 58) was assessed and scored as 
      MYC(low) (0-40 % of blasts) or MYC(high) (> 40 % of blasts). This was correlated 
      with MYC abnormalities by fluorescence in situ hybridization (FISH) and prognosis 
      in the context of cytogenetic risk stratification. Residual myeloid disease at 
      the end of induction was assessed by flow cytometry. MYC(low) and MYC(high) were 
      detected in 24 (41 %) and 34 cases (59 %), respectively. Extra copies of MYC were 
      present in 12 % of cases and were not correlated with level of MYC-IHC. No cases 
      had MYC translocation or amplification. Compared to MYC(low) patients, MYC(high) 
      patients had a shorter overall survival in all cytogenetic risk groups (68 vs. 21 
      months, p = 0.006) and in the intermediate risk group (61 vs. 21 months, p = 
      0.046). MYC(high) patients had a tendency towards detected residual disease at 
      the end of induction in all cytogenetic risk and intermediate risk groups. 
      Regardless of the underlying mechanisms of MYC dysregulation, high level of MYC 
      protein is expressed in the majority of AML and correlated to worse prognosis. 
      Further studies on MYC dysregulation in leukemogenesis and therapy targeting MYC 
      aberration are warranted.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Chen, Pu
AU  - Chen P
AD  - Departments of Pathology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA; Department of Laboratory Medicine, Zhongshan Hospital Fudan 
      University, Shanghai, China.
FAU - Redd, Lucas
AU  - Redd L
AD  - Departments of Pathology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Schmidt, Yao
AU  - Schmidt Y
AD  - Departments of Pathology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Koduru, Prasad
AU  - Koduru P
AD  - Departments of Pathology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Fuda, Franklin
AU  - Fuda F
AD  - Departments of Pathology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Montgomery-Goecker, Crystal
AU  - Montgomery-Goecker C
AD  - Departments of Pathology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Kumar, Kirthi
AU  - Kumar K
AD  - Departments of Pathology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Xu-Monette, Zijun
AU  - Xu-Monette Z
AD  - Departments of Hematopathology, University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Young, Ken
AU  - Young K
AD  - Departments of Hematopathology, University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Collins, Robert
AU  - Collins R
AD  - Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 
      USA.
FAU - Chen, Weina
AU  - Chen W
AD  - Departments of Pathology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA. Electronic address: weina.chen@utsouthwestern.edu.
LA  - eng
PT  - Journal Article
DEP - 20210424
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Cytogenetic Analysis
MH  - *Gene Expression
MH  - Humans
MH  - *Immunohistochemistry
MH  - Immunophenotyping
MH  - *In Situ Hybridization, Fluorescence
MH  - Leukemia, Myeloid, Acute/*genetics/*metabolism/mortality
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-myc/*genetics/*metabolism
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Cytogenetics
OT  - MYC
OT  - Prognosis
EDAT- 2021/05/03 06:00
MHDA- 2021/08/31 06:00
CRDT- 2021/05/02 20:48
PHST- 2020/12/23 00:00 [received]
PHST- 2021/03/27 00:00 [revised]
PHST- 2021/04/19 00:00 [accepted]
PHST- 2021/05/03 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2021/05/02 20:48 [entrez]
AID - S0145-2126(21)00085-0 [pii]
AID - 10.1016/j.leukres.2021.106584 [doi]
PST - ppublish
SO  - Leuk Res. 2021 Jul;106:106584. doi: 10.1016/j.leukres.2021.106584. Epub 2021 Apr 
      24.